GoodRx Holdings, Inc. (GDRX) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A indicate strong growth in Pharma Direct and condition-specific subscriptions, with optimistic guidance for 2026. Despite some uncertainties in partnerships and PTR revenue, the overall sentiment is positive due to expected revenue and EBITDA growth, as well as strong demand for GLP-1 therapies. The market cap suggests moderate stock price reaction, leading to a 'Positive' prediction (2% to 8%).
Key Financial Performance
Revenue $194 million, representing a 24% year-over-year decline. The decline was attributed to continued lapping impacts from 2025 and unit economics pressure.
Adjusted EBITDA $58.3 million, representing an adjusted EBITDA margin of 30%. No specific year-over-year change or reasons were mentioned.
Prescription Transactions Revenue $113.7 million, down 24% year-over-year. The decline was due to continued lapping impacts from 2025 and unit economics pressure.
Pharma Direct Revenue $52.2 million, up 82% year-over-year. The growth was driven by strong momentum with manufacturer partnerships and the successful launch of the Wegovy pill.
Subscription Revenue $24.4 million, up 16% year-over-year. The increase was supported by the ongoing adoption of condition-specific offerings.
Monthly Active Consumers 5.3 million, flat sequentially. No year-over-year change or reasons were mentioned.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Pharma Direct Growth: Pharma Direct saw 82% growth year-over-year, driven by manufacturer-sponsored pricing programs and GLP-1 access. Over 125 self-pay programs are live, including collaborations with Viatris and Pfizer for savings on medications.
Subscription Offerings: GoodRx for weight loss and other condition-specific programs are growing. Subscriptions increased 16% year-over-year to $24.4 million, with expanded offerings for FDA-approved GLP-1 therapies.
E-commerce Expansion: E-commerce retail network expanded significantly, with order volume and total claims doubling quarter-over-quarter. Direct contracts with 9 of the top 10 retail pharmacies are in place.
Employer Channel Expansion: GoodRx Employer Direct allows employers to subsidize manufacturer-sponsored pricing for employees, with examples like Eli Lilly's Zepbound KwikPens.
Operational Efficiencies: Direct retailer agreements and enhanced pricing capabilities improve consumer experience and marketplace economics.
Strategic Positioning: GoodRx is evolving from a pricing solution to a consumer access platform, enabling manufacturers to deliver self-pay programs directly to consumers.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Prescription Transactions Revenue Decline: Prescription transactions revenue decreased by 24% year-over-year, reflecting ongoing economic pressures and challenges in unit economics.
Unit Economics Pressure: The company continues to face challenges in unit economics, which could impact profitability and financial performance.
Coverage Gaps and Uninsured Consumers: Widening coverage gaps and an increasing number of uninsured consumers could create affordability challenges, potentially impacting consumer engagement and revenue.
Out-of-Pocket Costs: Elevated out-of-pocket costs for consumers may affect their ability to afford medications, influencing prescription transaction volumes.
Regulatory and Market Evolution: The evolving healthcare environment, including regulatory changes and market dynamics, poses risks to the company's strategic execution and adaptability.
Dependence on Manufacturer Partnerships: The company's growth in Pharma Direct and subscription revenue is heavily reliant on manufacturer partnerships, which could be a risk if these partnerships are disrupted or fail to scale as expected.
Employer Channel Expansion Risks: The expansion into the employer channel with new pricing models and subscription offerings may face adoption challenges or operational hurdles.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2026: The company expects revenue to be in the range of $765 million to $785 million for the full year 2026.
Adjusted EBITDA Guidance for 2026: Adjusted EBITDA is expected to be at least $235 million for the full year 2026.
Pharma Direct Revenue Growth: Pharma Direct revenue is expected to grow over 50% year-over-year in 2026, driven by strong momentum in consumer direct pricing offerings.
Subscription Revenue Growth: Subscription revenue is expected to build throughout 2026 as condition-specific programs continue to scale.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the change in view on the PTR revenue base embedded in the new guidance?
A:Prescription transaction revenue met internal expectations. MAC was slightly up quarter-over-quarter, and the full-year guidance being down 24% is in line with expectations. Focus is on Pharma Direct and condition-specific subscriptions.
Q:What is driving the improvement in the subscription base?
A:GoodRx's brand recognition, consumer engagement, competitive pricing, connectivity to a broad retail network, and exceptional service are key drivers. Early momentum was achieved with reduced marketing spend, and more marketing dollars will be invested throughout the year.
Q:Can you provide an update on the Surescripts partnership and its impact on the quarter?
A:Nothing material to report at this point. The partnership is ongoing, but no significant financial impact or contribution to guidance.
Q:Can you provide details on the volume reduction in the integrated savings program (ISP)?
A:There is no volume reduction in 2026. The referenced reduction is associated with 2025 and is not recurring this year. ISP programs are performing consistently with expectations, and volume is stable.
Q:Are there any changes in behavior from manufacturers regarding marketing spend?
A:No significant changes in behavior. Manufacturers are leaning in more due to GoodRx's demonstrated ROI and the regulatory environment pushing affordability and direct-to-patient programs. The number of deals is slightly down, but the dollar amount of deals is higher, leading to positive contributions.
Q:Is the Rx Marketplace stabilizing in terms of transactions and monthly MAC?
A:MAC is expected to flatten. Sequential declines from last year have stabilized, with slight quarter-over-quarter increases. The trajectory is more flatlined compared to last year, but some pressure remains.
Q:How does the concentration of retail pharmacy players impact GoodRx?
A:GoodRx works with all top players and is somewhat indifferent to where consumers choose to go. Retailer profitability in partnership with GoodRx is strong, and direct deals prioritize margin accretion. The loss of Rite Aid was significant, but future shifts in consumer preferences are not expected to have an outsized impact.
Q:What is the total number of prescriptions processed by GoodRx, and is it growing?
A:Consolidated prescription transactions across the business have not been disclosed. However, MAC is flat, and Pharma Direct is growing, implying overall growth in total prescriptions processed.
Q:Did weather impact the quarter's performance?
A:Weather events caused temporary volume dips, but these typically recover in the following week. The flu season was longer and later than expected, but no significant impact was noted.
Q:How is revenue from subscriptions and Pharma Direct recognized?
A:The $39 monthly subscription fee is recognized in the subscription line. Revenue from point-of-sale buydown programs is included in Pharma Direct. GoodRx does not gross up drug revenue like some peers.
Q:What is the growth outlook for Pharma Direct?
A:Pharma Direct is expected to grow sequentially throughout the year, with 50%+ growth projected. GLP-1 therapies are a significant growth driver, and the regulatory environment supports long-term opportunities.
Q:What is the trajectory of Wegovy Pill transactions, and how does it contribute to revenue?
A:Wegovy Pill transactions have shown strong performance due to strategic launch efforts, consumer familiarity, and supply availability. Demand for GLP-1 therapies remains strong, and contributions are expected to continue throughout the year.
Q:How is GoodRx allocating marketing dollars in 2026 compared to 2025?
A:Marketing dollars are being directed more towards condition-specific subscription offerings in 2026, with less emphasis on general brand advertising.
Q:What are the trends for PTR revenue beyond 2026?
A:PTR revenue is expected to be down 24% year-over-year in 2026, with a flattening trajectory. Macro factors like uninsured rates and Medicaid eligibility changes are being monitored for future impacts.
Q:What are the economics of the TrumpRx partnership?
A:Most volume from TrumpRx is incremental, with new consumers on the platform. GoodRx's direct deals with pharma determine pricing, and there is no contractual relationship with TrumpRx.
Q:How does GoodRx differentiate its GLP-1 offering?
A:GoodRx leverages its brand recognition, high NPS with prescribers, broad retail network connectivity, and consumer engagement. These factors differentiate it from competitors that lack a broad retail network.
Q:Review of Unclear Management Responses
A:Management avoided providing direct answers or lacked clarity on the following questions: 1. Update on the Surescripts partnership – No material updates or significant financial impact were provided. 2. Total prescriptions processed by GoodRx – Consolidated data was not disclosed, and management only implied growth. 3. Trends for PTR revenue beyond 2026 – Management did not provide long-term guidance or specific details on when PTR revenue might stabilize.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
FDA
GLP therapy
GoodRx pricing
GoodRx weight
Lilly
Pill
TrumpRx
adoption
channel GoodRx
condition program
consumer GoodRx
consumer pricing
consumer way
driver momentum
employee
employer channel
employer way
engagement platform
expansion commerce
journey
launch
loss offering
manufacturer pricing
offering Subscription
patient demand
pay pricing
pharmacy availability
platform self
prescription transaction
pricing offering
pricing pharmacy
pricing program
role GoodRx
scale
self pay
storefront
subscription offering
therapy pharmacy
way access
weight loss
GDRX Transcript
GoodRx Holdings, Inc. (GDRX) Q1 2026 Earnings Call Transcript
Positive5-8
The earnings call summary and Q&A indicate strong growth in Pharma Direct and condition-specific subscriptions, with optimistic guidance for 2026. Despite some uncertainties in partnerships and PTR revenue, the overall sentiment is positive due to expected revenue and EBITDA growth, as well as strong demand for GLP-1 therapies. The market cap suggests moderate stock price reaction, leading to a 'Positive' prediction (2% to 8%).
GoodRx Holdings, Inc. (GDRX) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call reveals strong growth prospects, including a 35% YoY increase in Manufacturer Solutions revenue and strategic investments in e-commerce and subscriptions, despite a slight revenue decline due to timing. Positive trends in Pharma Direct and increasing web traffic, alongside durable partnerships, indicate optimism. However, margin pressures and lower take rates are concerns, but the overall sentiment remains positive due to the company's strategic direction and market expansion efforts. The market cap suggests moderate stock volatility, aligning with a positive prediction.
GoodRx Holdings, Inc. (GDRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
GoodRx Holdings, Inc. (GDRX) Q3 2025 Earnings Call Transcript
Positive11-5
The earnings call summary and Q&A indicate strong growth prospects, particularly in manufacturer solutions and strategic initiatives, despite some headwinds like Rite Aid bankruptcy. The positive sentiment is reinforced by management's optimistic guidance and strategic focus on market expansion and partnerships. The market cap suggests a moderate reaction, leading to a 'Positive' prediction for stock price movement.
GDRX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
